Long lasting synthetic glucagon-like peptide (GLP-1)
First Claim
Patent Images
1. A method for treating diabetes in a patient, comprising administering to the patient an amount of D-Ala8 GLP-1 (7-36)-Lys37 (ε
- -(AEEA)-MPA)-NH2 effective to stimulate insulin secretion.
3 Assignments
0 Petitions
Accused Products
Abstract
Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
139 Citations
4 Claims
-
1. A method for treating diabetes in a patient, comprising administering to the patient an amount of D-Ala8 GLP-1 (7-36)-Lys37 (ε
- -(AEEA)-MPA)-NH2 effective to stimulate insulin secretion.
-
2. A method for enhancing the expression of insulin in a patient, comprising administering to the patient an amount of D-Ala8 GLP-1 (7-36)-Lys37(ε
- -(AEEA)-MPA)-NH2 effective to enhance insulin expression.
-
3. A method for treating diabetes in a patient, comprising administering to the patient an amount of a composition comprising D-Ala8 GLP-1 (7-36)-Lys37(ε
- (AEEA)-MPA)-NH2 effective to stimulate insulin secretion.
-
4. A method for enhancing the expression of insulin in a patient, comprising administering to the patient an amount of a composition comprising D-Ala8 GLP-1 (7-36)-Lys37(ε
- -(AEEA)-MPA)-NH2 effective to enhance insulin expression.
Specification